With a fresh leadership team…
With a fresh leadership team settling in, CNS Pharmaceuticals is [...]
Salspera has set out plans for a…
Salspera has set out plans for a $91 million IPO [...]
Less than a week after Roche…
Less than a week after Roche pledged a hefty investment [...]
Molecular glue-focused biotech f5…
Molecular glue-focused biotech f5 Therapeutics has failed to stick around [...]
The FDA has resumed review of…
The FDA has resumed review of Capricor Therapeutics’ previously rejected [...]
Bristol Myers Squibb’s…
Bristol Myers Squibb’s mezigdomide has scored its first phase 3 [...]
Xenon Pharmaceuticals’…
Xenon Pharmaceuticals’ anti-seizure candidate has smashed a pivotal trial out [...]
Shanghai-based Tenacia…
Shanghai-based Tenacia Biotechnology is making a $308 million biobucks move [...]
After a tumultuous tenure marked…
After a tumultuous tenure marked by recent clashes with the [...]
The FDA is ending a roughly…
The FDA is ending a roughly nine-month hiatus of drug-related [...]